.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Impact of CAR T-Cell Therapy for DLBCL

EP. 1: Initial Steps for Treatment of DLBCL

May 25th 2018

EP. 2: Emerging CAR T-Cell Therapies

May 25th 2018

EP. 3: Clinical Significance of the JULIET Trial

May 25th 2018

EP. 4: Practical Implications of CAR T-Cell Therapy

May 25th 2018

EP. 5: Future Outlook of CAR T-Cell Therapy for DLBCL

May 25th 2018

EP. 6: Candidates for CAR T-Cell Therapy in DLBCL

May 25th 2018

EP. 7: Selecting from CAR T-Cell Therapies in DLBCL

May 25th 2018

EP. 8: Lymphodepletion for CAR T-Cell Therapies in DLBCL

May 25th 2018

EP. 9: Response Data from the JULIET Trial in DLBCL

May 25th 2018

EP. 10: DLBCL: Managing Toxicities of CAR T-Cell Therapy

May 25th 2018

EP. 11: CAR T-Cell Therapy in DLBCL: Centers of Excellence

May 25th 2018